News Column

New Breast Cancer Findings Has Been Reported by Investigators at Federal University (Controlled release of raloxifene by nanoencapsulation: effect on...

July 24, 2014



New Breast Cancer Findings Has Been Reported by Investigators at Federal University (Controlled release of raloxifene by nanoencapsulation: effect on in vitro antiproliferative activity of human breast cancer cells)

By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology have been published. According to news reporting originating from Porto Alegre, Brazil, by NewsRx correspondents, research stated, "Raloxifene hydrochloride (RH) is considered to be an antiproliferative agent of mammary tissue. The aim of this study was to investigate the effect of the encapsulation of RH in polymeric nanocapsules with anionic or cationic surface on its release profile and antiproliferative activity."

Our news editors obtained a quote from the research from Federal University, "They were prepared by interfacial deposition of preformed polymer, followed by wide physicochemical characterization. The in vitro RH release was assessed by the dialysis membrane method and the data analyzed by mathematical modeling. The antiproliferative effect on MCF-7 cell viability was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as well as by counting viable cells. They had high encapsulation efficiency, low polydispersity, and nanometric mean size. Nanocapsules prepared with Eudragit() RS100 and Eudragit() S100 presented positive and negative zeta potentials, respectively. Drug release studies demonstrated controlled release of RH from anionic nanocapsules, which could be explained due to a stronger interaction of the drug to these nanocapsules and the larger amount of entrapped drug. On the other hand, this control was not observed from cationic nanocapsules due to the larger amount of drug adsorbed onto their surface. MCF-7 cell viability studies and cell counting showed that RH-loaded Eudragit() RS100 nanocapsules promote the best antiproliferative activity after 24 hours of treatment, whereas the best activity was observed for RH-loaded Eudragit() S100 nanocapsules after 72 hours."

According to the news editors, the research concluded: "Furthermore, the combined treatment of these formulations improved the antiproliferative effect during the entire treatment."

For more information on this research see: Controlled release of raloxifene by nanoencapsulation: effect on in vitro antiproliferative activity of human breast cancer cells. International Journal of Nanomedicine, 2014;9():2979-2991. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Oncology).

The news editors report that additional information may be obtained by contacting M.C. Fontana, Univ Fed Rio Grande do Sul, Fac Pharm, Pharmaceut Sci Grad Program, BR-90610000 Porto Alegre, RS, Brazil. Additional authors for this research include A. Beckenkamp, A. Buffon and R.C.R. Beck.

Keywords for this news article include: Antiproliferative Activity, Brazil, Therapy, Oncology, Porto Alegre, South America, Breast Cancer, Women's Health, Drug Development, Controlled Release

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Women's Health Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters